News|Articles|October 31, 2024
WCG Randomized 1,600 Participants for RSV Vaccine Trial
Author(s)WCG Clinical
A top 5 sponsor turned to WCG to recruit expecting mothers for its Phase III RSV vaccine trial. WCG support covered multiple countries and contributed almost one third of overall randomizations in the supported countries, bringing the study in ahead of schedule despite delays due to COVID-19 impacts on RSV seasonality. The sponsor met study timeline past enrollment by continuing to work with WCG’s retention support.
Trending on Applied Clinical Trials Online
1
2026 DIA Global Annual Meeting: Why Protocol Digitization Has Been So Hard to Automate—Until Now
2
2026 DIA Global Annual Meeting: What the FDA's Real-Time Data Push Actually Means for Sponsors and CROs
3
One Strategy, Two Jurisdictions: Unlocking Efficiency Across EU CTR and UK Regulatory Reform
4
ACT Brief: Real-Time Data Harmonization Infrastructure, Modern Trial Payments, and SCLC Drug Confirmatory Failure
5